Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Hosseini, Mina; Robat-Jazi, Behrouz; Shaygannejad, Vahid; Naffisi, Shahriar; Mirmossayeb, Omid; Rezaei, Abbas; Mansourian, Marjan; Esmaeil, Nafiseh

doi:10.1159/000486037

Cited by 10 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no significant differences in the Th22:Tc22 ratio in MG patients compared with those measured 6 months after TE (p = 0.665). Simultaneously with the assessment of Th22 and Tc22 cells, we also analyzed Th17 and Tc17 cells in these patients, the results of which have been published [25]. We found a positive correlation between Th17/Th22 and Tc17/Tc22 cells in healthy subjects (r = 0.597, p = 0.04; Fig.…”

Section: The Decrease Of Th22 and Tc22 Cells In Mg Patients After Tementioning

confidence: 61%

See 1 more Smart Citation

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Robat-Jazi

Hosseini

Shaygannejad

et al. 2018

Neuroimmunomodulation

Self Cite

View full text Add to dashboard Cite

Objectives: Myasthenia gravis (MG) is an autoimmune disease accompanied by a thymic pathology and in most patients thymectomy (TE) is used as the therapeutic approach. Both B and T cells play an important role in MG pathogenesis. Methods: Twelve pre- and post-TE MG patients and 12 healthy controls (HCs) were enrolled. The mean percentages of Th22 and Tc22 cells were evaluated in MG patients (before and 6 months after TE) and HCs. Results: The mean percentage of Tc22 cells in pre-TE patients was significantly higher than in HCs (p < 0.05), and after TE Tc22 cells significantly decreased compared to pre-TE (p < 0.05). The frequency of Th22 cells in pre-TE MG patients was not significantly different from HCs, but after TE Th22 cells were significantly decreased compared to pre-TE (p < 0.05). Conclusion: Our findings suggest a possible role of Th22 and Tc22 in MG pathogenesis.

show abstract

Section: The Decrease Of Th22 and Tc22 Cells In Mg Patients After Tementioning

confidence: 61%

“…Also, we assessed Th17 and Tc17 cells in these patients, and we found that these cells were elevated in comparison with healthy subjects, and their frequency decreased after TE [60]. Th22 and Th17 cells express multiple chemokine receptors, including CCR6, CCR4, and CCR10 [61,62].…”

Section: Discussionmentioning

confidence: 89%

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Robat-Jazi

Hosseini

Shaygannejad

et al. 2018

Neuroimmunomodulation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Th17 cells, which secrete IL-17, participate in the progression of MG. Hosseini et al. reported that the increased frequency of Th17 cells was closely correlated with the clinical severity of MG patients ( 28 ). Treg play a crucial role in immune homeostasis.…”

Section: Discussionmentioning

confidence: 99%

Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center

et al. 2022

View full text Add to dashboard Cite

BackgroundLymphoplasma exchange (LPE), a technique combining plasma exchange with leukapheresis, is emerging as promising treatment for autoimmune diseases. Data on the efficacy and safety of LPE in myasthenia gravis (MG) therapy are scarce. In this study, we aimed to comprehensively review the clinical efficacy, safety, and immunological characteristics of LPE therapy in MG patients.Study Design and MethodsA Chinese cohort of 276 generalized MG patients in state of exacerbation, including impeding crisis, myasthenia crisis, and preparation for thoracic exsection between January 2014 and December 2020, were evaluated in this study.ResultsA total of 276 patients with a median age of 45.5 ± 16.7 years underwent a total of 635 LPE sessions. Clinical scales of Quantitative Myasthenia Gravis (QMG) scores, Myasthenia Gravis Specific Manual Muscle Testing (MMT) scores, activities of daily living (ADL) scores, and quality of life (QOL) scores were improved during 4 weeks’ follow-up. Adverse effects occurred in 20 out of 276 patients, with 14 patients having one adverse event each. Independent predictive factors for good response to LPE therapy were symptom onset before LPE therapy ≤3 days and age on LPE therapy <50 years of age. LPE decreased the serum levels of antibodies, immunoglobulins, and complements 4 weeks after the first replacement, with decreased levels of interleukin (IL)-17A and interferon (IFN)-γ and increased level of IL-10.ConclusionLPE is an effective treatment for MG patients in state of exacerbation and preparation for thymectomy. Early use of LPE on early-onset MG may have good therapeutic effects. The potential mechanism for LPE is the polarization of cytokines from IL-17A, IFN-γ, into IL-10.

show abstract

“…This was likely being driven by the high leverage AChR+ MG observations. MG is generally considered a CD4 T cell dependent disease, and little recent research has focused on the CD8 + T cell population in MG 15,29,30 . However, there is evidence that nonthymomatous AChR+ MG patients with late‐onset disease have increased CD8 + T cell populations with a phenotype suggestive of recent thymic emigration, 30 and AChR+ MG patients have increased frequencies of CD8 + T cells producing IL‐17 and IL‐17/IFNγ 15 .…”

Section: Discussionmentioning

confidence: 99%

Reduced plasmablast frequency is associated with seronegative myasthenia gravis

et al. 2020

View full text Add to dashboard Cite

Background The immunopathology of autoimmune seronegative myasthenia gravis (SN MG) is poorly understood. Our objective was to determine immune profiles associated with a diagnosis of SN MG. Methods We performed high‐dimensional flow cytometry on blood samples from SN MG patients (N = 68), healthy controls (N = 46), and acetylcholine receptor antibody (AChR+) MG patients (N = 27). We compared 12 immune cell subsets in SN MG to controls using logistic modeling via a discovery‐replication design. An exploratory analysis fit a multinomial model comparing AChR+ MG and controls to SN MG. Results An increase in CD19+CD20−CD38hi plasmablast frequencies was associated with lower odds of being a SN MG case in both the discovery and replication analyses (discovery P‐value = .0003, replication P‐value = .0021). Interleukin (IL) ‐21 producing helper T cell frequencies were associated with a diagnosis of AChR+ MG (P = .004). Conclusions Reduced plasmablast frequencies are strongly associated with a SN MG diagnosis and may be a useful diagnostic biomarker in the future.

show abstract

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis

Cited by 10 publications

References 41 publications

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy

Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center

Reduced plasmablast frequency is associated with seronegative myasthenia gravis

Contact Info

Product

Resources

About